DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia

Tumor Biology

Volumn 37, Issue 7, 2016, Pages 8951-8960

  Zhou, Jing dong ^a   Zhang, Ting juan ^a   Wang, Yu xin ^a   Yang, Dong qin ^a   Yang, Lei ^a   Ma, Ji chun ^a   Wen, Xiang mei ^a   Yang, Jing ^a   Lin, Jiang ^a   Qian, Jun ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

AML; DLX4; Expression; Methylation; Prognosis

Indexed keywords

DECITABINE; ISOPROTEIN; MESSENGER RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DLX4; TRANSCRIPTION FACTOR DLX7; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DLX4 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BP1 GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CLINICAL INDICATOR; CONTROLLED STUDY; DE NOVO ACUTE MYELOID LEUKEMIA; DEMETHYLATION; DISEASE ASSOCIATION; DLX4 GENE; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; KASUMI 1 CELL LINE; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; THP1 CELL LINE; ACUTE MYELOID LEUKEMIA; DRUG EFFECTS; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; REMISSION; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DEOXYCYTIDINE; DNA METHYLATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; REMISSION INDUCTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84954176546     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4364-4     Document Type: Article

References (42)

1. Estey E, Döhmer H. Acute myeloid leukaemia. Lancet. 2006;368:1894–907.
2. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114:1150–7.
3. Avivi I, Rowe JM. Prognostic factors in acute myeloid leukemia. Curr Opin Hematol. 2005;12:62–7.
4. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29:475–86.
5. Marchesi F, Annibali O, Cerchiara E, Tirindelli MC, Avvisati G. Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. Crit Rev Oncol Hematol. 2011;80:331–46.
6. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:497–529.
7. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.
8. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2002;2:777–85.
9. Kraus P, Lufkin T. Dlx homeobox gene control of mammalian limb and craniofacial development. Am J Med Genet A. 2006;140:1366–74.
10. Mpollo MS, Beaudoin M, Berg PE, Beauchemin H, D’Agati V, Trudel M. BP1 is a negative modulator of definitive erythropoiesis. Nucleic Acids Res. 2006;34:5232–7.
11. Tomida S, Yanagisawa K, Koshikawa K, Yatabe Y, Mitsudomi T, Osada H, et al. Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene. 2007;26:4600–8.
12. Trinh BQ, Barengo N, Naora H. Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-β cytostatic program and blocks the antiproliferative effect of TGF-β. Oncogene. 2011;30:2718–29.
13. Zhang L, Yang M, Gan L, He T, Xiao X, Stewart MD, et al. DLX4 upregulates TWIST and enhances tumor migration, invasion and metastasis. Int J Biol Sci. 2012;8:1178–87.
14. Sun Y, Lu X, Yin L, Zhao F, Feng Y. Inhibition of DLX4 promotes apoptosis in choriocarcinoma cell lines. Placenta. 2006;27:375–83.
15. Miyamoto K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Asahara T, Sugimura T, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer. 2005;116:407–14.
16. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, et al. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010;5:499–508.
17. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP. DNA methylation biomarkers for lung cancer. Tumor Biol. 2012;33:287–96.
18. Sakane J, Taniyama K, Miyamoto K, Saito A, Kuraoka K, Nishimura T, et al. Aberrant DNA methylation of DLX4 and SIM1 is a predictive marker for disease progression of uterine cervical low-grade squamous intraepithelial lesion. Diagn Cytopathol. 2015;43:462–70.
19. Harada H, Miyamoto K, Yamashita Y, Taniyama K, Ohdan H, Okada M. Methylated DLX4 predicts response to pathologic stage I non-small cell lung cancer resection. Ann Thorac Surg. 2015;99:1746–54.
20. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–5.
22. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.
23. Li Y, Lin J, Yang J, Qian J, Qian W, Yao DM, et al. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res. 2013;37:1642–7.
24. Zhou JD, Yang L, Zhang YY, Yang J, Wen XM, Guo H, et al. Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia. Med Oncol. 2015;32:386.
25. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2011;6:e26906.
26. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2012;91:519–25.
27. Yang X, Qian J, Sun A, Lin J, Xiao G, Yin J, et al. RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. Clin Biochem. 2013;46:579–83.
28. Qian J, Yao DM, Lin J, Qian W, Wang CZ, Chai HY, et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2012;7:e45760.
29. Wen XM, Lin J, Yang J, Yao DM, Deng ZQ, Tang CY, et al. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol. 2014;7:6832–40.
30. Zhou JD, Wang YX, Zhang TJ, Yang DQ, Yao DM, Guo H, et al. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia. Biochem Biophys Res Commun. 2015;463:1250–6.
31. Zhang TJ, Zhou JD, Yang DQ, Wang YX, Yao DM, Ma JC, et al. Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome. Clin Chem Lab Med. 2015.
32. Oki Y, Issa JP. Epigenetic mechanisms in AML—a target for therapy. Cancer Treat Res. 2010;145:19–40.
33. Shaknovich R. Gene expression and epigenetic deregulation. Adv Exp Med Biol. 2013;792:133–50.
34. Gao Y, Li Z, Guo X, Liu Y, Zhang K. DLX4 as a prognostic marker for hepatocellular carcinoma. Neoplasma. 2014;61:318–23.
35. Yu M, Wan YF, Zou QH. Prognostic significance of BP1 mRNA expression level in patients with non-small cell lung cancer. Clin Biochem. 2008;41:824–30.
36. Yu M, Yang Y, Shi Y, Wang D, Wei X, Zhang N, et al. Expression level of beta protein 1 mRNA in Chinese breast cancer patients: a potential molecular marker for poor prognosis. Cancer Sci. 2008;99:173–8.
37. Haga SB, Fu S, Karp JE, Ross DD, Williams DM, Hankins WD, et al. BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia. 2000;14:1867–75.
38. Zhou JD, Yang J, Guo H, Deng ZQ, Wen XM, Yang L, et al. BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia. Leuk Lymphoma. 2015:1–19.
39. Xie XH, Xu XP, Sun CY, Yu ZJ. Regulation of the oncogenic function of distal-less 4 by microRNA-122 in hepatocellular carcinoma. Mol Med Rep. 2015;12:1375–80.
40. Woods BA, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev. 2015;263:22–35.
41. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599–612.
42. Ilagan JO, Ramakrishnan A, Hayes B, Murphy ME, Zebari AS, Bradley P, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25:14–26.